Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

RGA Investment Advisors - Maravai: Two Elite Assets With Other-Worldly Margins Wrapped In One [Seeking Alpha]

Maravai LifeSciences Holdings, Inc. - Class A common stock (MRVI) 
Company Research Source: Seeking Alpha
Maravai's subsidiaries, TriLink and Cygnus, play critical roles in NAP and BS segments, with unique assets and capabilities. Maravai's strong margin structure, EBITDA performance, and potential for growth through mRNA applications and quality control testing make it a promising investment. The following segment was excerpted from this fund letter. Maravai LifeSciences Holdings, Inc. ( NASDAQ: MRVI We first purchased shares of Maravai early in Q3 of 2023. Much like our experience with META in 2022, almost immediately following our first purchases, the stock's price Recommended For You Recommended For You About MRVI Stock More on MRVI Related Stocks Trending Analysis Trending News Show less Read more
Impact Snapshot
Event Time:
MRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for MRVI alerts
Opt-in for
MRVI alerts

from News Quantified
Opt-in for
MRVI alerts

from News Quantified